



---

# 2020 ANNUAL REPORT

**Who are we**

**Our Institutional  
Partners**

**Our Data Entry  
Operators**

**HCC Registry**

**Research**

**Education &  
Training**

**Publications**

**Financial Report**

**Connect with us**

<https://hemecancer.org/>

# WHO ARE WE

Hematology Cancer Consortium (HCC) is a multi center collaborative organization established to fulfil the long felt need of good quality, cooperative group data in hematological malignancies in India.


## OUR GOALS

- Aggregate clinical data to support care outcomes of hematological malignancies
- Develop evidence based, locally relevant treatment protocols and guidelines
- Run investigator initiated prospective collaborative clinical trials addressing regionally relevant questions and evaluating cost effective treatment strategies
- Continuous education to improve awareness and enhance knowledge of therapeutic options for standardization of care in hematological cancers



# OUR INSTITUTIONAL PARTNERS

We began with 12 leading Cancer Centers as our institutional partner and we currently have 17 partners.



# OUR DATA ENTRY OPERATORS



**R. RAJESH**

**DATA ENTRY OPERATOR  
JAWAHARLAL INSTITUTE OF POSTGRADUATE  
MEDICAL EDUCATION AND RESEARCH (JIPMER),  
PUDUCHERRY**



**K. BOMMI**

**DATA ENTRY OPERATOR  
CHRISTIAN MEDICAL COLLEGE (CMC), VELLORE**




**AAKRITI KAPOOR**

**DATA ENTRY OPERATOR  
POST GRADUATE INSTITUTE OF MEDICAL  
EDUCATION & RESEARCH (PGIMER), CHANDIGARH.**

# HCC REGISTRY


One of the goals of Hematology Cancer Consortium is to aggregate clinical data to support care outcomes of hematological malignancies.

In the year 2020, seventeen centers across the country recorded 774 Acute Myeloid Leukemia patients' information. The center wise distribution has been summarized in the graph.




# HCC REGISTRY

In the year 2020, fifteen centers across the country recorded 784 Acute Lymphocytic Leukemia patients' information. The center wise distribution has been summarized in the graph.




In the year 2020, twelve centers across the country recorded 106 Acute Promyelocytic Leukemia patients' information. The center wise distribution has been summarized in the graph.




# HCC REGISTRY

In the year 2020, fifteen centers across the country recorded 354 Chronic Myeloid Leukemia patients' information. The center wise distribution has been summarized in the graph.



In the year 2020, fourteen centers across the country recorded 776 Lymphoma patients' information. The center wise distribution has been summarized in the graph.



# RESEARCH

## Induction Related Mortality Score in Acute Myeloid Leukemia: Prospective Validation Study

**Indication:** All newly diagnosed and treated cases of acute myeloid leukemia (with either intensive induction chemotherapy or less intensive therapy)

**Aim & Objectives:**

**Primary Objectives:**

- To validate the Induction Mortality Score developed by HCC in a multicenter prospective cohort of patients with AML receiving induction therapy
- To develop an online calculator for induction mortality score in AML

**Study design:** A prospective, multicenter cohort study.

**Duration of study:** 4 years

**Date of Study commencement:** 1st July, 2020

**No of Centers participating in this study:** 17

## Evaluation of the safety and efficacy of generic low-dose Dasatinib for frontline therapy in chronic phase chronic myeloid leukemia - A multi-center phase II single arm study

**Indication:** Newly diagnosed Chronic phase Ph-chromosome positive chronic myeloid leukemia

**Aim & Objectives:**

**Primary Objectives:**

- To evaluate the 12-month molecular response rate (Bcr-Abl <1%) of generic low dose Dasatinib in newly diagnosed patients with chronic phase chronic myeloid leukemia

**Study design:** A multi-center phase II, single arm study.

**Duration of study:** 2 years

**Date of Study commencement:** October, 2020

**No of Centers participating in this study:** 12



# RESEARCH

## COVID-19 Hematological Cancers Registry of India (CHCRI)

**Indication:** Patients diagnosed with hematological malignancies who are also diagnosed to have COVID-19 infection based on COVID-19 RT-PCR or antigen testing

### Aim & Objectives:

- To collect data on the demographics and clinical manifestations of patients with hematological malignancies who develop SARS CoV2 infection.
- To analyse the characteristics of SARS-CoV-2 infection and all-cause mortality, COVID-19 related mortality and hematologic cancer-related mortality and morbidity outcome in patients suffering from hematologic cancers based on pre-defined COVID-19 risk categorization and WHO ordinal scale
- To analyze the demographics and clinical characteristics of patients with hematologic malignancies who develop second episode of COVID-19 or who develop COVID-19 after 1 or two doses of COVID vaccination.

**Study design:** Observational (Registry)

**Duration of study:** 5 years

**Date of Study commencement:** 1st November, 2020

**No of Centers participating in this study:** 11

# EDUCATION & TRAINING

**WEBINAR TOPIC: LEVERAGING T-CELL ENGAGING IMMUNOTHERAPY FOR THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA**

**IN ASSOCIATION WITH  
SOCIETY OF HEMATOLOGIC ONCOLOGY (SOHO) AND  
PHYSICIANS' EDUCATION RESOURCE® (PER®)**

## SPEAKERS

**Elias Jabbor, MD**  
MD Anderson Cancer Center, Houston, TX, USA

**Nikita Mehra, MD, DM**  
Cancer Institute (WIA), Adyar, Chennai, India

**Hagop M Kantarjian, MD**  
MD Anderson Cancer Center, Houston, TX, USA

**Prasanth Ganesan, MD, DM**  
JIPMER, Puducherry, India

**In addition to this HCC has conducted webinars on various topics**

| Topic   | Speaker(s)  |
|---|---|
| Common challenges in management of hematological malignancies in COVID era                                | <b>Multiple speakers</b>  |
| Current Evidence in Management of CLL & Future Direction  | <b>Dr. Nitin Jain</b> , MD Associate Professor<br>Department of Leukemia MD Anderson<br>Cancer Center Houston, TX             |
| What can our chromosomes tell us?<br>Relevance of cytogenetic assessment in<br>hematological malignancies | <b>Dr. Nancy Beryl Janet</b> . A Lecturer,<br>Department of Haematology Christian<br>Medical College, Vellore                 |
| A Primer on Molecular Testing in<br>Haematology & MRD in AML  | <b>Dr. Madhavi Maddali</b> , MD, DNB, Assistant<br>Professor, Department of Haematology<br>Christian Medical College, Vellore |

# EDUCATION & TRAINING

Cont..

| Topic   | Speaker(s)  |
|---|---|
| Overview of Cytomorphology in Hematological Malignancies    | <b>Brig Tathagata Chatterjee</b> COL S Venkatesan                                       |
| Immunophenotyping: Basic Interpretation for a Clinician     | <b>Dr. Prashant Tembhare</b> , Hematopathology Laboratory, ACTREC, Tata Memorial Center |
| ASH 2020 Update   | <b>Multiple Speakers</b>  |
| How to evaluate flow and interpret flow cytometry based MRD | <b>Dr. Prashant Tembhare</b> , Hematopathology Laboratory, ACTREC, Tata Memorial Center |
| What's new in CLL - ASH 2020 Updates                        | <b>Dr. Pankaj Malhotra</b> , PGI, Chandigarh  |
| COVID Vaccination and Hematological Cancers                 | <b>Dr. Priya Sampathkumar</b> , MD, Division of Infectious Disease, Mayo Clinic         |

# PUBLICATIONS

- **Publication 1:**

**Title-**

**Outcomes in adolescent and young adult acute lymphoblastic leukaemia: a report from the Indian Acute Leukaemia Research Database(INwARD) of the Hematology Cancer Consortium (HCC)**

**Authors-**

Prasanth Ganesan, Hasmukh Jain, Bhausahab Bagal, Papagudi G. Subramanian, Biju George, Anu Korula, Nikita Mehra, Jayachandran P. Kalaiyarasi, Dinesh Bhurani, Narendra Agrawal, Rayaz Ahmed, Smita Kayal, Jina Bhattacharyya, Uday Yanamandra, Suman Kumar, Chepsy C. Philip, M. Joseph John, Ambily Nadaraj, Omprakash Karunamurthy, Jeyaseelan Lakshmanan, Vikram Mathews, Manju Sengar.

**Publication details-** British Journal of Haematology

**DOI:** 10.1111/BJH.17268

- **Publication 2:**

**Title-**

**Hematological Cancer Consortium: Multi-Center Acute Myeloid Leukemia Registry Data from India**

**Authors-**

Rajan Kapoor, Hasmukh Jain, Anu Korula, Dinesh Bhurani, Venkatraman Radhakrishnan, Chepsy C Philip, Jina Bhattacharyya, Maitreyee Bhattacharyya, Smita Kayal, Pankaj Malhotra, Govind Babu, Lalit Kumar, Om Prakash, Ambily Nadaraj, Jeyaseelan Lakshmanan, Biju George, Poonkuzhali Balasubramanian, Bhausahab Bagal, Satyaranjan Das, Rayaz Ahmed, Prasanth Ganesan, Gaurav Prakash, Nikita Mehra, Manju Sengar, and Vikram Mathews

**Publication details-** Blood 2018; 132 (Supplement 1): 4006.

**DOI:** <https://doi.org/10.1182/blood-2018-99-116853>

# FINANCIAL REPORT

## Balance sheet as at March 31, 2021

M/s Hematology Cancer Consortium- Association

Balance Sheet as At March 31, 2021

In ₹ (Rupees)

| Particulars                   | Note No. | 9 Jan-2020 to 31-Mar-2021 |             |
|-------------------------------|----------|---------------------------|-------------|
|                               |          |                           |             |
| <b>EQUITY AND LIABILITIES</b> |          |                           |             |
| <b>Sources of Funds</b>       |          |                           |             |
| (a) Corpus fund               |          |                           | 30,69,964   |
| (b) Reserves and Surplus      |          |                           |             |
| <b>Current Liabilities</b>    |          |                           |             |
| (a) Trade Payables            | 1        | 30,69,964                 |             |
| (b) Other Current Liabilities | 2        |                           | 77,63,185   |
| <b>Total</b>                  |          |                           |             |
| <b>ASSETS</b>                 |          |                           |             |
| <b>Non-Current Assets</b>     |          |                           |             |
| (a) Other Non-Current Assets  | 3        | 32,291                    | 32,291      |
| <b>Current Assets</b>         |          |                           |             |
| (a) Cash and Cash Equivalents | 4        |                           | 1,08,00,858 |
| (b) Prepaid Expenditure       |          | 1,07,15,475               |             |
| (c) Misc Expenditure          |          | 71,204                    |             |
|                               |          | 14,179                    |             |
| <b>Total</b>                  |          |                           |             |
| <b>1,08,33,149</b>            |          |                           |             |

Significant Accounting Policies & Notes to Accounts

As per our report attached.  
For M. P. Chitale & Co.  
Chartered Accountants  
Firm Regn. No.101851W

For and On behalf of the Board  
M/s Hematology Cancer Consortium- Association

Ashutosh Pednekar  
Partner  
M No.: 041037  
Date:- September 30, 2021  
Place:- Mumbai

Dr. Vikram Mathews  
Director

Dr. Manju Sehgar  
Director

# FINANCIAL REPORT

## Statement of Income and Expenditure for the period ended March 31, 2021

M/s Hematology Cancer Consortium- Association

Statement of Income and Expenditure for the period ended March 31, 2021

In ₹ (Rupees)

| SR No | Particulars                              | Note No. | 9-Jan-2020 to 31-Mar-2021 |
|-------|--|----------|---------------------------|
| I     | Donations, Grants & Sponsorships         | 5        | 52,41,936                 |
| II    | Other Income                             | 6        | 1,25,485                  |
| III   | TOTAL REVENUE (I + II)                   |          | 53,67,421                 |
| IV    | EXPENSES                                 |          |                           |
|       | Expenses on Objects of Section 8 Company | 7        | 22,97,457                 |
|       | TOTAL EXPENSES                           |          | 22,97,457                 |
| V     | Surplus Before Tax                       |          | 30,69,964                 |
| VI    | Tax Expense                              |          |                           |
|       | Current Tax                              |          | -                         |
|       | Deferred Tax                             |          | -                         |
| VII   | Surplus for the Period(V-VI)             |          | 30,69,964                 |

The Notes referred to above form an integral part of the Balance Sheet.

As per our report attached.  
For M. P. Chitale & Co.  
Chartered Accountants  
Firm Regn. No.101851W

Ashutosh Pednekar  
Partner  
M No.: 041037  
Date:- September 30, 2021  
Place:- Mumbai

For and On behalf of the Board  
M/s Hematology Cancer Consortium- Association

Dr. Vikram Mathews  
Director

Dr. Manju Sengar  
Director

# FINANCIAL REPORT

## Cash flow statement

M/s Hematology Cancer Consortium- Association

**Cash flow statement**  
for the period ended March 31, 2021

(Currency: Indian rupees)

| Particulars  | 9-Jan-2020<br>to<br>31-Mar-2021 |
|--|---------------------------------|
| <b>A. Cash flow from operating activities</b>                    |                                 |
| Surplus Before Tax   | 30,69,964                       |
| <i>Adjustments for:</i>  |                                 |
| Depreciation and amortization expenses                           |                                 |
| <b>Operating cash flows before changes in assets/liabilities</b> | 30,69,964                       |
| <b>Changes in assets/liabilities</b>                             |                                 |
| Increase/(decrease) in trade payables                            |                                 |
| Increase/(decrease) in other current liabilities                 | 77,63,185                       |
| Increase/(decrease) in short-term provisions                     | -                               |
| (Increase)/decrease in Other Non current Assets                  | (32,291)                        |
| (Increase)/decrease in short-term loans and advances             | (85,383)                        |
| <b>Cash generated from operating activities</b>                  | 1,07,15,475                     |
| Taxes paid   |                                 |
| <b>Net cash flows generated from operating activities (A)</b>    | 1,07,15,475                     |
| <b>B. Cash flow from investing activities</b>                    |                                 |
| Purchase of fixed assets   |                                 |
| <b>Net cash flow generated from investing activities (B)</b>     |                                 |
| <b>C. Cash flow from financing activities</b>                    |                                 |
| Issue of share capital   |                                 |
| <b>Net cash flow generated from financing activities (C)</b>     |                                 |
| <b>Net increase in cash and cash equivalents (A+B+C)</b>         | 1,07,15,475                     |
| Cash and Cash Equivalents as at the beginning of the year        |                                 |
| <b>Cash and Cash Equivalents as at the end of the year</b>       | 1,07,15,475                     |

The Notes referred to above form an integral part of the Balance Sheet.

As per our report attached.  
For M. P. Chitale & Co.  
Chartered Accountants  
Firm Regn. No.101851W

For and On behalf of the Board  
M/s Hematology Cancer Consortium- Association

Ashutosh Pednekar  
Partner  
M No: 041037  
Date: September 30, 2021  
Place: Mumbai

Dr. Vikram Mathews  
Director  
Date:

Dr. Manju Sengar  
Director  
Date:

# FINANCIAL REPORT

## Schedules

M/s Hematology Cancer Consortium- Association

**Schedule 1 Reserves & Surplus**

|   | 9-Jan-2020<br>to<br>31-Mar-2021 |
|---|---------------------------------|
| Opening Balance                               | -                               |
| Add: Surplus carried over from balance sheet  | 30,69,964                       |
| Less: Deficit carried over from balance sheet | -                               |
| <b>Total</b>                                  | <b>30,69,964</b>                |

**Schedule 2 Current liabilities & provisions**



|                           | 9-Jan-2020<br>to<br>31-Mar-2021 |
|---------------------------|---------------------------------|
| Sundry Creditors          | -                               |
| Payable to Director(s)    | 23,631                          |
| Audit Fee Payable         | 25,000                          |
| Professional Fees Payable | 13,874                          |
| Grant Payable (Tata)      | 77,00,679                       |
| <b>Total</b>              | <b>77,63,184</b>                |

**Schedule 3 Other Non-Current Assets**

|                           | 9-Jan-2020<br>to<br>31-Mar-2021 |
|---------------------------|---------------------------------|
| TDS Receivable FY 2020-21 | 32,065                          |
| TDS Payable (Extra Paid)  | 226                             |
| <b>Total</b>              | <b>32,291</b>                   |

**Schedule 4 Cash & Bank Balances**

|  | 9-Jan-2020<br>to<br>31-Mar-2021 |
|--|---------------------------------|
| Cash in hand   | -                               |
| Bank Balances in Savings Account with HDFC Bank, Worli-Sandoz House Branch |                                 |
| Account No. 50100347097089   | 27,70,628                       |
| Account No. 50100392097440   | 79,19,847                       |
| Fixed Deposits   | 25,000                          |
| <b>Total</b>   | <b>1,07,15,475</b>              |



# FINANCIAL REPORT

## Schedules

cont..

**M/s Hematology Cancer Consortium- Association**

**Schedule 5 Donations, Grants & Sponsorships**



|              | 9-Jan-2020<br>to<br>31-Mar-2021 |
|--------------|---------------------------------|
| Donation     | 27,50,000                       |
| Grant        | 3,54,321                        |
| Sponsorship  | 21,37,615                       |
| <b>Total</b> | <b>52,41,936</b>                |

**Schedule 6 Other Income**

|                      | 9-Jan-2020<br>to<br>31-Mar-2021 |
|----------------------|---------------------------------|
| Saving Bank Interest | 1,25,485                        |
| <b>Total</b>         | <b>1,25,485</b>                 |

**Schedule 4 Expenses on Objects of Section 8 Company**

|                                      | 9-Jan-2020<br>to<br>31-Mar-2021 |
|--------------------------------------|---------------------------------|
| Amortization of preliminary expenses | 9,452                           |
| Insurance                            | 52,696                          |
| Audit Fee                            | 25,000                          |
| Interest on TDS                      | 5,060                           |
| Website charges                      | 64,900                          |
| Late fee Income Tax                  | 1,000                           |
| Professional Fees                    | 17,17,445                       |
| Research Activity                    | 4,21,904                        |
| <b>Total</b>                         | <b>22,97,457</b>                |



# CONNECT WITH US

**HCC is deeply grateful to its individual & corporate supporters for their generosity.**

**You can join us on:**



**CONTACT US**

**EMAIL: [ADMIN@HEMECANCER.ORG](mailto:ADMIN@HEMECANCER.ORG)**